Human insulin drugs are used in the treatment of diabetes by regulating blood sugar levels in patients. It is produced using recombinant DNA technology and acts as a substitute for the insulin produced by the pancreas. Diabetes is a chronic disease that occurs when the pancreas is unable to produce enough insulin or the body cannot effectively use the insulin it produces. This leads to an increase in blood sugar levels. The growing prevalence of diabetes globally has created a surge in demand for human insulin drugs as a viable treatment option.

The global Human Insulin Drug Market is estimated to be valued at US$ 49411.32 Mn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics
The growing prevalence of diabetes driven by increasing risk factors such as obesity, lack of physical activity, and unhealthy diet is a key factor augmenting the growth of the human insulin drug market. Nearly half a billion people worldwide are estimated to suffer from diabetes by 2030 according to the World Health Organization. Human insulin drugs help control blood sugar levels and mitigate diabetes related health complications. Furthermore, technological advancements in insulin delivery systems including insulin pumps and pens that provide more convenient and controlled insulin administration are also fueling the adoption of human insulin drugs. The availability of long-acting human insulin analogs offering enhanced glycemic control compared to regular human insulin has further expanded the application scope of these drugs.

Segment Analysis
The human insulin drug market can be segmented into types, mode of application, end users, and distribution channel. Based on types, it is divided into short-acting insulin, intermediate insulin, and premixed insulin. Short-acting insulin dominates the market with over 40% share as it provides quick action for controlling blood sugar levels after meals. Among mode of application, intravenous segment holds the largest share due to higher efficiency and reliability of intravenous insulin administration in management of conditions like diabetic ketoacidosis. Key end users include hospitals and clinics, home care settings, and others. Hospitals and clinics are the major end users due to higher number of patients preferring hospital settings for initial treatment and management of diabetes. Retail pharmacies represented the largest distribution channel in the market.

PEST Analysis
Political: Governments across regions are supporting initiatives to increase awareness about diabetes and promote affordable insulin drugs. However, regulations around pricing transparency and strict approvals impact market growth.
Economic: Rising incidence of diabetes due to changing lifestyles and growing elderly population drives the need for effective drug management. However, pricing pressures and economic uncertainties impact the market.
Social: Increasing health consciousness and initiatives to manage diabetes through physical activity and dietary modifications influence the market. However, social stigma around insulin dependence restrains market growth.
Technological: Advanced insulin analogs providing faster action and precision dosing have been developed. Artificial pancreas systems automating insulin delivery witness higher adoption. However, constraints in developing affordable innovative technologies impact the market.

Key Takeaways
The Global Human Insulin Drug Market Size is expected to witness high growth. The market size for 2023 is US$ 49411.32 Mn. Regionally, North America dominates the market with over 35% value share. Factors such as growing prevalence of diabetes, favorable reimbursement policies, rapid adoption of technologically advanced insulin drugs, and presence of key players drive the regional market. Key players operating in the human insulin drug market include Wockhardt, SEDICO, Exir, Julphar, Biocon, Eli Lilly, Sanofi Aventis, and Novo Nordisk AS, among others. Key players focus on developing affordable biosimilar and analog insulin drugs. Key players also engage in new product approvals and launches to consolidate their market positions.

Regional analysis:
Regional analysis related content comprises The Asia Pacific region is expected to witness the fastest growth during the forecast period. This can be attributed to improving access to diabetes care, increasing healthcare expenditures, rising medical tourism, and presence of cost-effective generics producers in the region. China and India represents the most lucrative markets in the region.

Key players:
Key players operating in the human insulin drug market are Wockhardt, SEDICO, Exir, Julphar, Biocon, Eli Lilly, Sanofi Aventis, and Novo Nordisk AS. Key players focus on developing affordable biosimilar and analog insulin drugs to expand their market shares. Eli Lilly and Novo Nordisk AS occupy dominant market positions while Wockhardt, SEDICO and Exir focus on generic human insulin drugs.

Get more insights on this topic:

https://www.dailyprbulletin.com/human-insulin-drug-market-size-market-share-analysis/